Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0CW8S
|
|||
Drug Name |
ABX-1431
|
|||
Synonyms |
SQZJGTOZFRNWCX-UHFFFAOYSA-N; CHEMBL3945728; SCHEMBL15100632; BDBM180052; US9133148, 9aq
Click to Show/Hide
|
|||
Indication | Neuropathic pain [ICD-11: 8E43.0] | Phase 1 | [1] | |
Tourette syndrome [ICD-11: 8A05.00; ICD-10: F95.2] | Phase 1 | [1] | ||
Company |
Abide Therapeutics San Diego, CA
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H22F9N3O2
|
|||
Canonical SMILES |
C1CCN(C1)C2=C(C=CC(=C2)C(F)(F)F)CN3CCN(CC3)C(=O)OC(C(F)(F)F)C(F)(F)F
|
|||
InChI |
1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2
|
|||
InChIKey |
SQZJGTOZFRNWCX-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1446817-84-0
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Monoglyceride lipase (MAGL) | Target Info | Inhibitor | [1] |
BioCyc | Triacylglycerol degradation | |||
KEGG Pathway | Glycerolipid metabolism | |||
Metabolic pathways | ||||
Retrograde endocannabinoid signaling | ||||
NetPath Pathway | EGFR1 Signaling Pathway | |||
Reactome | Acyl chain remodeling of DAG and TAG | |||
Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | ||||
WikiPathways | Lipid digestion, mobilization, and transport | |||
Glycerophospholipid biosynthesis | ||||
GPCR downstream signaling | ||||
Effects of PIP2 hydrolysis |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.